Titelbild

Press releases

2017-11-02 – Press release

Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund

  • Corporate venture fund invests EUR 4 million (USD 5 million) into Topas
  • Financing to accelerate clinical trials in autoimmune diseases
  • Detlev Mennerich, Ph.D., Investment Manager of BIVF, to join Topas’ Board ofDirectors

read more …

2017-10-26 – Press release

Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer

  • Highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Bayer and Schering
  • To lead Topas’ clinical development and regulatory affairs

read more …

2017-08-22 – Press release

Topas Therapeutics signs multi-year research and option agreement with Lilly focused on immune tolerance

read more …

2017-04-04 – Press release

Paul Sekhri joins Topas Therapeutics as Chairman of the Board

read more …

2016-03-22 – Press release

Evotec spins off auto-immune disease company as ‘Topas Therapeutics GmbH’

  • Topas Therapeutics GmbH is based on a proprietary nanoparticle platform which supports antigen-specific tolerance induction for multiple indications
  • Strong consortium consisting of Epidarex Capital, EMBL Ventures, Gimv and Evotec AG supports strategic Series A financing round of EUR 14 m
  • Initiation of first clinical trials expected in 2017

read more …